A new study shows that India’s widely used commercial antivenom is largely ineffective against the highly toxic red-tailed pit viper, highlighting an urgent need for region-specific treatments to save lives in Northeast India.
Did you play Scidle, the science wordle today?
Researchers have discovered that the country’s standard snakebite treatment is largely ineffective against the venom of the red-tailed pit viper (Trimeresurus erythrurus), a snake found throughout Northeast India. In a new study, a research team from the Institute of Advanced Study in Science and Technology (IASST), the Academy of Scientific and Innovative Research (AcSIR), Amrita Vishwa Vidyapeetham, and Tezpur University has shown that the widely used Indian polyvalent antivenom fails to properly bind to or neutralise the lethal toxins of this specific viper. Consequently, the antivenom offers only partial protection, failing to stop severe internal organ damage or reverse deadly blood-clotting issues.
Snakebites are a major public health crisis in India, causing an estimated 2.7 million cases of envenomation annually. However, current treatments are proving dangerously inadequate for rural and agricultural communities living in regions with unique snake populations, with antivenoms constantly failing. To understand why the treatment was failing, the researchers collected venom from red-tailed pit vipers in Mizoram and tested it against two major commercial Indian antivenoms. They used a combination of biochemical laboratory tests and live animal models to observe the venom’s effects.
In the lab, they mixed the venom and antivenom to see whether the antivenom antibodies could recognise and bind the venom’s toxic proteins, such as snake venom metalloproteinases, which are known to cause severe bleeding and tissue destruction. They discovered that the antibodies in the standard antivenom only weakly recognised the pit viper’s toxins. When they tested the mixture in mice, the results were alarming. Even with massive doses of antivenom, the mice still suffered from abnormal blood cell counts, brain congestion, and severe damage to their hearts, livers, and kidneys.
The standard Indian antivenom is produced using the venom of the ‘Big Four’ snakes: the spectacled cobra, common krait, saw-scaled viper, and Russell’s viper. Because the red-tailed pit viper belongs to a completely different evolutionary subfamily called Crotalinae, its venom contains a unique cocktail of proteins. The antibodies in the standard antivenom are trained exclusively to fight the Big Four, meaning they do not have the correct molecular shape to bind the distinct toxins of the red-tailed pit viper.
Earlier work by the same team had shown that the Indian antivenom also struggled against another local snake, Pope’s pit viper. This new study shows that the red-tailed pit viper also faces the same issue, perhaps more lethal. It requires a significantly higher dose of antivenom for even marginal survival in mice, exposing a much wider gap in treatment efficacy than previously known.
The research once again provides a crucial wake-up call, showing that a one-size-fits-all approach to snakebites does not work for a country with such diverse wildlife. The study has laid the groundwork for a major shift in public health policy. Developing next-generation, region-specific antivenoms that include the venom of local snakes like the red-tailed pit viper will reduce the required treatment dosages, lower the risk of severe allergic reactions to the antivenom itself, and, most importantly, save countless lives in Northeast India.
Weekly Science, Technology, Engineering, Arts, & Math Quizzes
New questions every week!
Leave a Reply